Xilio Therapeutics, Inc.
Xilio Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $43.8 million, up 589.9% from fiscal 2024. In the quarter to June 2026, revenue grew 131.2%, EPS grew 85.3% and free cash flow fell 26.2%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years; insiders bought in the last twelve months.
Follow XLO
A Balance Sheet is a financial statement that provides a snapshot of a company's assets, liabilities, and shareholders' equity at a specific point in time. It follows the formula: Assets = Liabilities + Shareholders' Equity. Key components include current and non-current assets, current and long-term liabilities, and equity. The Balance Sheet helps businesses and investors evaluate financial stability, liquidity, and capital structure. It's essential for assessing the company's ability to meet its obligations and fund future operations.
| Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|
Cash and Short Term Investments |
48.85 | 19.24 | 198.05 | 120.39 | 44.70 | 55.29 | 137.53 |
Receivables |
— | — | — | — | — | — | 5.00 |
Other current assets |
2.26 | — | — | — | — | — | — |
Total current assets |
51.10 | 20.59 | 202.52 | 124.50 | 48.13 | 60.23 | 145.03 |
Property, Plant, Equpment (Net) |
9.87 | 7.37 | 7.62 | 7.26 | 5.94 | 4.47 | 3.89 |
Long-Term Investments |
0.19 | — | — | — | — | — | — |
Long-term assets (Other) |
1.55 | 2.05 | 1.95 | 1.83 | 1.73 | 1.78 | 1.81 |
Total non-current assets |
— | 15.73 | 15.54 | 14.67 | 12.80 | 10.84 | 9.66 |
Total Assets |
62.72 | 36.32 | 218.06 | 139.17 | 60.93 | 71.08 | 154.69 |
Notes Payable |
— | 2.33 | — | 6.67 | 3.32 | — | — |
Accounts Payable |
2.52 | 5.44 | 3.14 | 3.13 | 1.05 | 2.57 | 3.17 |
Accrued Expenses |
— | 13.73 | 8.75 | 10.33 | 10.50 | 9.98 | 11.74 |
Current Revenue (Deferred) |
— | — | — | — | — | 13.52 | 40.02 |
Other current liabilities |
2.69 | 0.08 | 0.08 | 0.08 | 0.05 | — | — |
Total current liabilities |
5.21 | 22.16 | 12.78 | 21.12 | 15.96 | 27.26 | 56.27 |
Long Term Debt (Total) |
18.63 | 7.41 | 9.63 | 3.17 | — | — | — |
Non-current Revenue (Deferred) |
— | — | — | — | — | 19.26 | 20.64 |
Non-current Liabilities (Other) |
0.37 | 1.13 | 0.12 | 0.05 | — | — | 36.89 |
Total non-current liabilities |
— | 19.45 | 19.85 | 12.40 | 8.14 | 26.22 | 63.14 |
Total liabilities |
24.21 | 41.60 | 32.63 | 33.52 | 24.10 | 53.48 | 119.41 |
Additional Paid In Capital |
— | 1.80 | 346.31 | 354.75 | 362.34 | 401.35 | 454.06 |
Preferred Stock (Total) |
— | 78.00 | — | — | — | — | — |
Common Stock (Net) |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | — |
Retained Earnings |
(29.87) | (85.09) | (160.89) | (249.11) | (325.51) | (383.75) | (418.79) |
Common Equity (Total) |
(29.52) | (83.29) | 185.43 | 105.65 | 36.83 | 17.60 | 35.27 |
Shareholders Equity (Total) |
38.51 | (5.28) | 185.43 | 105.65 | 36.83 | 17.60 | 35.27 |
Shareholders Equity and Liabilities (Total) |
— | 36.32 | 218.06 | 139.17 | 60.93 | 71.08 | 154.69 |
Shares (Common) |
— | 0.05 | 1.95 | 1.96 | 1.97 | 3.27 | 4.53 |
Shares (Preferred) |
— | 4.77 | — | — | — | — | — |
Shareholders Equity (Tangible) |
— | (5.28) | 185.43 | 105.65 | 36.83 | 17.60 | 35.27 |
Net Debt |
(30.21) | (11.83) | (188.42) | (117.22) | (44.70) | (55.29) | (137.53) |
Total Debt |
18.63 | 7.41 | 9.63 | 3.17 | — | — | — |